Nanozola subcutaneous injection 30mg syringe

Nanozola subcutaneous injection 30mg syringe, manufactured by Taisho Pharmaceutical, contains Ozoralizumab (genetical recombination). Ozoralizumab is a next-generation TNF inhibitor, specifically a humanized trivalent Nanobody compound, approved for the treatment of rheumatoid arthritis (RA). It works by potently inhibiting TNF-alpha activity. It is supplied as a 30mg/0.375mL/1 tube injectable drug (YJ code: 3999467G1023).